Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
MK-8507, a long-acting NNRTI, will be tested in a weekly regimen with islatravir.
HIV blogger and activist Mark S. King turns 60 with a digital blowout celebrating all long-term survivors and featuring A-list celebs.
A new long-acting injectables HIV drug shows promise in monkey study.
The first generic Truvada is now available in the United States.
More studies link dolutegravir and other drugs to weight gain among people with HIV.
The city launched a program to start people on treatment within six days of diagnosis in 2015.
Pooled results from recent studies found a high rate of full viral suppression and no major safety concerns.
In launching a new grassroots network, Latinx people living with HIV define their own agenda.
Feeling sad or blue is common, but persistent depression can be treated.
The novel attachment inhibitor led to viral suppression in 60% of people with extensive prior treatment.
The single-tablet regimen is now approved for previously treated people with an undetectable viral load.
Details of the federal initiative to end the epidemic
More diversity would help doctors determine whether coronavirus treatments and vaccines will work for all population groups.
A mid-stage trial shows islatravir plus Pifeltro shows promise as two-drug HIV regimen.
The immune modulator Pomalyst led to remission in two thirds of people with AIDS-related Kaposi sarcoma.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.